Moreover, JAK inhibition has been proposed to counteract drug resistance mechanisms; for instance, targeting JAK2 in EGFR-mutant lung adenocarcinoma can restore the effectiveness of EGFR inhibitors like erlotinib and gefitinib by modulating interactions with SOCS5. Here, EGFR is linked to lung adenocarcinoma.